Arcutis Biotherapeutics Inc (NASDAQ:ARQT) price on current trading day, fall -3.02% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $13.09.
A look at the stock’s price movement, the level at last check in today’s session was $13.50, moving within a range at $12.72 and $13.35. The beta value (5-Year monthly) was 1.778. Turning to its 52-week performance, $17.75 and $7.64 were the 52-week high and 52-week low respectively. Overall, ARQT moved -3.73% over the past month.
Arcutis Biotherapeutics Inc’s market cap currently stands at around $1.56 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-May-05.
Analysts have a consensus estimate of 72.7M for the company’s revenue for the quarter, with a low and high estimate of 69.62M and 74.9M respectively. The average forecast suggests up to a 135.61% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 310.51M, representing a 57.99% jump on that reported in the last financial year.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 2 recommend ARQT as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 1 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ARQT’s current price about -4.92% and -6.18% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 42.01, while 7-day volatility ratio is 0.54% and 2.96% in the 30-day chart. Further, Arcutis Biotherapeutics Inc (ARQT) has a beta value of 1.78, and an average true range (ATR) of 0.73. Analysts have given the company’s stock an average 52-week price target of $19, forecast between a low of $19 and high of $19. Looking at the price targets, the low is -45.15% off recent price level in today’s trading while to achieve the yearly target high, it has to move -45.15%. Nonetheless, investors will most likely welcome a -45.15% jump to $19 which is the analysts’ median price.
If we refocus on Arcutis Biotherapeutics Inc (NASDAQ:ARQT), historical trading data shows that trading volumes averaged 1.96 over the past 10 days and 2.30 million over the past 3 months. The company’s latest data on shares outstanding shows there are 119.14 million shares.
The 12.06% of Arcutis Biotherapeutics Inc’s shares are in the hands of company insiders while institutional holders own 98.78% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 16.78 million on 2025-05-30, giving us a short ratio of 7.77. The data shows that as of 2025-05-30 short interest in Arcutis Biotherapeutics Inc (ARQT) stood at 1741.0 of shares outstanding, with shares short rising to 15.14 million registered in 2025-04-30. Current price change has pushed the stock -6.01% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ARQT stock continues to rise going into the next quarter.
